Company profile
Commit Biologics
A pioneer in the activation of the complement system to treat cancer and autoimmune disease.
- Industry
- Biotechnology
- Employees
- 30
- Headquarters
- Aarhus, Middle Jutland
- Founded
- 2021
- LinkedIn followers
- 3,343
- Office locations
- 1
Commit Biologics company summary
Commit Biologics is a company in the Biotechnology industry, headquartered in Aarhus, Middle Jutland, founded in 2021. On LinkedIn the company has around 30 employees and 3,343 followers.
What technology does Commit Biologics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Commit Biologics
Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.
Where is Commit Biologics located?
Commit Biologics lists 1 location.
Compare companies similar to Commit Biologics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Commit Biologics commitbio.com | Biotechnology | 30 | 2021 | Aarhus, Middle Jutland |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Commit Biologics
What does Commit Biologics do?
Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.
How many employees does Commit Biologics have?
Commit Biologics has around 30 employees on LinkedIn.
Where is Commit Biologics headquartered?
Commit Biologics is headquartered in Aarhus, Middle Jutland.
When was Commit Biologics founded?
Commit Biologics was founded in 2021.
Build a lead list from companies like Commit Biologics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.